Alphamab Oncology (HK:9966) has released an update.
Alphamab Oncology has announced a voluntary share repurchase program, signaling strong confidence in the company’s value and future prospects. The Board has resolved to buy back shares up to HK$50 million, with the repurchase price capped at a 5% premium over the average closing price of the preceding five trading days. The move is aimed at aligning the current trading price with the company’s intrinsic value and enhancing shareholder value, although the repurchase will depend on market conditions and the Board’s discretion.
For further insights into HK:9966 stock, check out TipRanks’ Stock Analysis page.
